ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0397

Paediatric uveitis – Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom
Abstract Number: 0398

Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 0399

External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis
Abstract Number: 0400

Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Abstract Number: 0401

Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Abstract Number: 0402

Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Abstract Number: 0403

IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Abstract Number: 0404

Disease Extension in Children with Limited Juvenile Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 0405

Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study
Abstract Number: 0406

Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis
Abstract Number: 0407

The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Abstract Number: 0408

Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus
Abstract Number: 0409

Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 0410

Improving Outcomes in Patients with Juvenile Idiopathic Arthritis through a Novel Chronic Condition Value-Based Care Program
Abstract Number: 0411

Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].